High Levels of the PSA (Prostate Specific Antigen) In Patients with Benign Prostatic Hyperplasia and Prostate CancerRishu BansaliMedPub
New research shows that prostate specific antigen (PSA), a commonly used serum marker of prostate cancer, inhibits the formation of new blood vessels and consequently slows the progression of the disease (Journal of the National Cancer Institute 1999;91:1635-40).The finding may explain the ...
Dr. Lin and colleagues compared the 4KScore test with the Prostate Cancer Prevention Trial (PCPT) risk calculator in more than 1400 men. All had elevated PSA levels and were referred for biopsy at 26 centers in the United States from October 2013 to January 2014. SUGGESTED for you All of ...
researchers found that at least 8% of patients with this classification had a more aggressive form ofprostate cancer. They also found that many of the patients with GGG1 who are at highest risk can be identified based on high PSA levels or 50% or more of theirbiopsysamples coming back posi...
PSA levels can be detected in the blood, urine, or semen. Blood PSA testing is used as a screening test for prostate cancer. Prostate-specific antigen (PSA) levels by age remain the same across most populations. A PSA level above 4.0 ng/mL in any age group must be investigated. However...
On the right to the cladogram, plasma total prostate specific antigen (PSA) levels are placed on the timeline in dark gray, together with corresponding percent free PSA values in light gray when available. GP5 received dutasteride and finasteride for symptoms of benign prostatic hyperplasia during...
1Index date was the date of initial CaP diagnosis for prostate cancer (CaP) patients; the date of first elevated PSA test result for men with elevated PSA; the same index date as their matched cases for controls. CI = confidence interval. ...
Rewiring of energy metabolism and adaptation of mitochondria are considered to impact on prostate cancer development and progression. Here, we report on mitochondrial respiration, DNA mutations and gene expression in paired benign/malignant human prostat
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32(36):4066-4072.PubMedGoogle ScholarCrossref 41. Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous ...
Men whose prostate-specific antigen (PSA) level increases after radical prostatectomy or radiotherapy but who have no known metastases comprise the second-largest group of patients with prostate cancer. However, no standard of care exists for these patie